Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer

Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer INTRODUCTIONProstate cancer screening is accomplished by digital rectal examination (DRE) and serum prostate‐specific antigen (PSA) testing in at risk populations. Men with an elevated age‐specific serum PSA, serum PSA velocity of >0.35 ng/mL per year, or abnormal DRE are believed to be at risk for harboring occult prostate cancer thereby warranting discussion about the merits of prostate needle biopsy. The serum PSA test, however, has limitations in that non‐malignant conditions such as benign prostatic hyperplasia (BPH) and prostatic inflammation can generate non‐specific PSA elevations. Therefore, a high PSA may theoretically yield unnecessary prostate biopsy with resultant complications including infection, bleedings, urinary retention, and pain. Additional concerns entail the psychological stress about possibly having prostate cancer. Therefore, more specific biomarkers for prostate cancer are needed to make a more accurate recommendation for prostate biopsy.MicroRNAs (miRNAs) are small non‐coding RNAs that have the potential to be biomarkers for prostate cancer. They regulate gene expression, post‐transcriptionally, by targeting messenger RNA (mRNAs) and inhibiting their translation. They have been shown to be either down‐regulated or up‐regulated in cancers as well as involved in cellular processes that influence tumorigenesis such as differentiation, proliferation, and apoptosis, thus suggesting their role in cancers. For prostate cancer, studies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer

Loading next page...
 
/lp/wiley/circulating-micrornas-in-plasma-as-potential-biomarkers-for-the-early-f8bzM58ibo
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0270-4137
eISSN
1097-0045
D.O.I.
10.1002/pros.23485
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONProstate cancer screening is accomplished by digital rectal examination (DRE) and serum prostate‐specific antigen (PSA) testing in at risk populations. Men with an elevated age‐specific serum PSA, serum PSA velocity of >0.35 ng/mL per year, or abnormal DRE are believed to be at risk for harboring occult prostate cancer thereby warranting discussion about the merits of prostate needle biopsy. The serum PSA test, however, has limitations in that non‐malignant conditions such as benign prostatic hyperplasia (BPH) and prostatic inflammation can generate non‐specific PSA elevations. Therefore, a high PSA may theoretically yield unnecessary prostate biopsy with resultant complications including infection, bleedings, urinary retention, and pain. Additional concerns entail the psychological stress about possibly having prostate cancer. Therefore, more specific biomarkers for prostate cancer are needed to make a more accurate recommendation for prostate biopsy.MicroRNAs (miRNAs) are small non‐coding RNAs that have the potential to be biomarkers for prostate cancer. They regulate gene expression, post‐transcriptionally, by targeting messenger RNA (mRNAs) and inhibiting their translation. They have been shown to be either down‐regulated or up‐regulated in cancers as well as involved in cellular processes that influence tumorigenesis such as differentiation, proliferation, and apoptosis, thus suggesting their role in cancers. For prostate cancer, studies

Journal

The ProstateWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial